Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Aug 2018
Price :
$35
*
At a glance
- Drugs Vilazodone (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Actavis; Forest Laboratories
- 23 Jul 2018 Primary endpoint [Time to first relapse during the double-blind treatment phase ] has not been met, according to results published in the International Clinical Psychopharmacology
- 23 Jul 2018 Results (n=564) published in the International Clinical Psychopharmacology
- 17 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.